Cited by 724Cholesterol and Lipid MetabolismDrug Transport and Resistance MechanismsLipid metabolism and disorders

The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway

Open access
Lawn, Richard M., Wade, David P., Garvin, Michael R., Wang, Xingbo, Schwartz, Karen, Porter, J. Gordon, Seilhamer, Jeffrey J., Vaughan, Ashley M. +1 more·1999·Journal of Clinical Investigation

Abstract

The ABC1 transporter was identified as the defect in Tangier disease by a combined strategy of gene expression microarray analysis, genetic mapping, and biochemical studies. Patients with Tangier disease have a defect in cellular cholesterol removal, which results in near zero plasma levels of HDL and in massive tissue deposition of cholesteryl esters. Blocking the expression or activity of ABC1 reduces apolipoprotein-mediated lipid efflux from cultured cells, and increasing expression of ABC1 enhances it. ABC1 expression is induced by cholesterol loading and cAMP treatment and is reduced upon subsequent cholesterol removal by apolipoproteins. The protein is incorporated into the plasma membrane in proportion to its level of expression. Different mutations were detected in the ABC1 gene of 3 unrelated patients. Thus, ABC1 has the properties of a key protein in the cellular lipid removal pathway, as emphasized by the consequences of its defect in patients with Tangier disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci8119

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • ABCA1 is a protein involved in cholesterol efflux and translocation from the inner leaflet to the outer leaflet of the plasma membrane.

    “we identified ABCA1, a protein involved in cholesterol efflux and translocation from the inner leaflet to the outer leaflet of the plasma membrane (4, 27).”

    From Cholesterol efflux protein, ABCA1, supports anticancer functions of myeloid immune cells (2026) · cites this paper as [27]

    The Discussion (p. R25) identifies ABC1 as pivotal to apolipoprotein-mediated cholesterol efflux and says its cell-surface expression is consistent with lipid transport across the plasma membrane. It does not specify translocation of cholesterol from the inner to the outer leaflet; that mechanism is not established by the cited passages. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • ABCA1 transports cellular cholesterol and phospholipids from cells to lipid-poor apolipoproteins, including apoE, to form high density lipoproteins (HDL).

    “It transports cellular cholesterol and phospholipids from cells to lipid-poor apolipoproteins, including apoE, in order to form high density lipoproteins (HDL) (Figure 2) (Lawn et al., 1999).”

    From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Lawn et al., 1999

    The Discussion (Volume 104, R25) identifies ABC1 as pivotal to apolipoprotein-mediated lipid removal and says its cell-surface location is consistent with transport of cellular lipids to apolipoproteins. The Introduction links acquisition of cholesterol and phospholipids by nascent apo A-I to maturation into HDL. Our copy does not identify apoE as a recipient, and it presents ABC1’s direct transport role as consistent with the evidence rather than established. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • ABCA1 is a transmembrane protein that plays an important role in the efflux of cholesterol and phospholipids to lipid-poor apolipoproteins.

    “ABCA1 is a transmembrane protein that plays an important role in the efflux of cholesterol and phospholipids to lipid-poor apolipoproteins [39].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. Assmann, G., von Eckardstein, A., and Brewer, H.B. 1995. Familial HDL deficiency: Tangier disease. In The metabolic basis of inherited disease. C.R. Scriver, A.L. Beaudet, W.S. Sly, and D. Valle, editors. McGraw- Hill. New York, NY. 2053-2072.
  2. Rogler, G., Trümbach, B., Klima, B., Lackner, K.J., and Schmitz, G. 1995. HDL-mediated efflux of The Journal of Clinical Investigation | Volume 104 R31 intracellular cholesterol is impaired in fibroblasts from Tangier disease patients. Arterioscler. Thromb. Vasc. Biol. 15:683-690.
  3. Oram, J.F., Mendez, A.J., Lymp, J., Kavanagh, T.J., and Halbert, C.L. 1999. Reduction in apolipopro- tein-mediated removal of cellular lipids by immor- talization of human fibroblasts and its reversion by cAMP: lack of effect with Tangier disease cells. J. Lipid Res. In press.

Cited by

Sorted by citations

Authors
Lawn, R. M., Wade, D. P., Garvin, M. R., Wang, X., Schwartz, K., Porter, J. G., Seilhamer, J. J., Vaughan, A. M., & Oram, J. F.
Affiliations
University of Washington (US)
Corresponding author
Lawn, Richard M.
Venue
Journal of Clinical Investigation
Published
1999-10-15
Volume
104
Issue
8
Pages
R25-R31
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2032513433
Cited by
724
References
1
Citations by year
2026: 4 · 2025: 3 · 2024: 1 · 2023: 7 · 2022: 4 · 2021: 7 · 2020: 7 · 2019: 9 · 2018: 12 · 2017: 13 · 2016: 18 · 2015: 13 · 2014: 17 · 2013: 8 · 2012: 19
FWCI
84.04
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Incyte
  • National Institutes of Health (5r29hl053451-05)
  • National Heart, Lung, and Blood Institute (HL-55362, HL-53451, R01HL055362)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK 02456, P01DK002456)
Topics
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
Tangier disease, cholesterol efflux, HDL cholesterol, plasma membrane proteins, cholesterol loading, cyclic AMP
MeSH terms
Adolescent, Animals, Apolipoproteins, Cells, Cultured, Gene Expression Regulation, Glycoproteins, Humans, Male, Mutation, Tangier Disease, ATP-Binding Cassette Transporters, Lipid Metabolism, Mice, ATP Binding Cassette Transporter 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review